Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
Royalty Pharma (Nasdaq: RPRX) has appointed Dr. Ted W. Love as Lead Independent Director, as unanimously decided by the independent directors of the Board. Dr. Love, who has served as an independent director since 2020, will continue to Chair the Nominating and Corporate Governance Committee.
Dr. Love brings extensive research-based biopharma experience and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization's (BIO) Board of Directors. The appointment reinforces Royalty Pharma's commitment to strong corporate governance and strategic oversight.
Royalty Pharma (Nasdaq: RPRX) ha nominato il Dott. Ted W. Love come Lead Independent Director, deciso all’unanimità dai direttori indipendenti del Consiglio. Il Dott. Love, che ricopre il ruolo di direttore indipendente dal 2020, continuerà a presiedere il Comitato per la Nomina e la Governance Aziendale.
Il Dott. Love porta una vasta esperienza nel settore biopharma basato sulla ricerca e, attualmente, è Presidente Emerito del Consiglio di Amministrazione di BIO. Questa nomina rafforza l’impegno di Royalty Pharma verso una solida governance aziendale e una supervisione strategica.
Royalty Pharma (Nasdaq: RPRX) ha designado al Dr. Ted W. Love como Lead Independent Director, por unanimidad de los directores independientes de la Junta. El Dr. Love, que ha sido director independiente desde 2020, continuará presidiendo el Comité de Nominaciones y Gobierno Corporativo.
El Dr. Love aporta amplia experiencia en biotecnología basada en la investigación y actualmente es Expresidente del Consejo de Directores de BIO. El nombramiento refuerza el compromiso de Royalty Pharma con una sólida gobernanza corporativa y supervisión estratégica.
Royalty Pharma(Nasdaq: RPRX)가 독립 이사들 전원의 만장일치로 Ted W. Love 박사를 Lead Independent Director로 선임했습니다. 2020년부터 독립 이사로 재직해 온 Love 박사는 앞으로도 지명 및 기업 거버넌스 위원회의 의장을 계속 맡게 됩니다.
Love 박사는 연구를 토대로 한 광범위한 생명공학 분야의 경력을 보유하고 있으며 현재 BIO 이사회 의장의 즉시 전임(Immediate Past Chairman)으로 활동 중입니다. 이번 임명은 강력한 기업 거버넌스와 전략적 감독에 대한 Royalty Pharma의 약속을 강화합니다.
Royalty Pharma (Nasdaq : RPRX) a nommé le Dr Ted W. Love en tant que Lead Independent Director, à l’unanimité des administrateurs indépendants du conseil. Le Dr Love, qui siège en tant qu’administrateur indépendant depuis 2020, continuera de présider le Comité de mise en nomination et de gouvernance d’entreprise.
Le Dr Love apporte une expérience approfondie dans le secteur biopharmaceutique fondée sur la recherche et occupe actuellement le poste de Président sortant du Conseil d’administration de BIO. Cette nomination renforce l’engagement de Royalty Pharma envers une bonne gouvernance d’entreprise et une supervision stratégique.
Royalty Pharma (Nasdaq: RPRX) hat Dr. Ted W. Love zum Lead Independent Director ernannt, einstimmig von den unabhängigen Direktoren des Vorstands beschlossen. Dr. Love, der seit 2020 als unabhängiger Direktor tätig ist, wird weiterhin den Nominating and Corporate Governance Committee leiten.
Dr. Love bringt umfassende forschungsbasierte Biopharma-Erfahrung mit und ist derzeit der Immediate Past Chairman des BIO-Vorstands. Die Ernennung bekräftigt Royalty Pharmas Engagement für eine starke Unternehmensführung und strategische Aufsicht.
عينت Royalty Pharma (المُدرجة في ناسداك: RPRX) الدكتور تيد دبليو. لوف كمدير مستقل رئيسي، وبالإجماع من قبل المدراء المستقلين في المجلس. الدكتور لوف، الذي شغل منصب مدير مستقل منذ 2020، سيواصل رئاسة لجنة الترشيحات والحوكمة المؤسسية.
يُضيف الدكتور لوف خبرة واسعة في صناعة الأدوية الحيوية المعتمدة على البحث وهو حاليًا الرئيس السابق لمجلس BIO. تعزز هذه التعيينات التزام Royalty Pharma بحوكمة مؤسسية قوية وإشراف استراتيجي.
Royalty Pharma（纳斯达克股票代码：RPRX）任命 Ted W. Love 博士为首席独立董事，董事会独立董事一致通过。Love 博士自2020年起担任独立董事，将继续担任提名与公司治理委员会主席。
Love 博士在基于研究的生物制药领域拥有丰富经验，目前担任 BIO 董事会的即时前任主席（Immediate Past Chairman）。此次任命进一步强化了 Royalty Pharma 对良好公司治理和战略监督的承诺。
- None.
- None.
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee.
“I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. “Ted has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization’s (BIO) Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to his continued stewardship as we advance our mission to accelerate innovation in life sciences.”
“I am honored to be appointed Lead Independent Director,” said Ted. “Royalty Pharma’s pioneering approach to life sciences innovation and its commitment to long-term value creation make it a remarkable organization. I look forward to continuing my contributions to the Board, providing independent oversight and helping to guide the company’s strategic direction.”
About Ted W. Love, MD
Dr. Love serves as BIO’s Immediate Past Chair of its Board of Directors following a two-year term as Chairman (2023-2025). Previously, he served as President and CEO of Global Blood Therapeutics (GBT) as well as a member of its board. Before GBT, he was EVP, Research and Development and Technical Operations, at Onyx Pharmaceuticals. Prior to Onyx, Ted served as President, CEO and Chairman of Nuvelo. Earlier in his career, Ted served as SVP, Development, at Theravance and held a number of senior management positions in medical affairs and product development at Genentech, including as Chairman of Genentech’s Product Development Committee and VP, Product Development. Dr. Love serves on the Board of Directors of Gilead Sciences and Structure Therapeutics. Ted holds an MD from Yale Medical School and a BA in molecular biology from Haverford College. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
Who is the new Lead Independent Director of Royalty Pharma (RPRX)?
What experience does Dr. Ted Love bring to Royalty Pharma (RPRX)?
What roles will Dr. Ted Love hold at Royalty Pharma (RPRX)?
When did Dr. Ted Love join Royalty Pharma's (RPRX) Board?
